Company / EPS (Diluted)
Halozyme EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$2.10
FY2025
5-year range
-$0.50 / $2.74
FY2021-FY2025
Trend
+45.8%
vs FY2024
Sector context
#25 of 204
Health Care
What the data says
Halozyme's eps (diluted) of $2.10 is higher than 88% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-0.81 in FY2018 to $2.74 in FY2023.
Based on SEC 10-K filings.
2.10 in FY2025 with a 3-year CAGR of +32.1%. Top quartile in the Health Care sector.
Declined from $2.74 to $2.10 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +32.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 204This company $2.10 Sector average -$0.98
▼
+314.4% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 45.8% year-over-year.
- Ranks #25 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.10 | +45.8% |
| FY2024 | $1.44 | -47.4% |
| FY2023 | $2.74 | +201.1% |
| FY2022 | $0.91 | +282.0% |
| FY2021 | -$0.50 | +10.7% |
| FY2020 | -$0.56 | -224.4% |
| FY2019 | $0.45 | +155.6% |
| FY2018 | -$0.81 | -224.0% |
| FY2017 | -$0.25 | -31.6% |
| FY2016 | -$0.19 | -1050.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026